The Genetic Counseling Outcome Scale: a new patient-reported outcome measure for clinical genetics services

The Genetic Counseling Outcome Scale: a new patient-reported outcome measure for clinical genetics services
复制标题

DOI:
10.1111/j.1399-0004.2011.01636.x
复制
发表时间:
2011-05-01
期刊:
影响因子:
3.5
通讯作者:
Todd, C.
Todd, C.
中科院分区:
医学2区
文献类型:
--
作者:
McAllister, M.;Wood, A. M.;Todd, C.

文献摘要

被引文献

相似文献

本研究的目的是开发一种临床遗传学服务的患者报告结果测量(PROM)。先前的研究被用来制定一份84项问卷草案,由527名患者支持小组成员完成。回答进行探索性因素分析(EFA)。平行分析用于确定使用倾斜旋转提取的因子数量。选择24个问题组成遗传咨询结果量表(GCOS-24)。241名患者在参加遗传学诊所之前和之后完成了一份问卷,其中包括GCOS-24,并验证了健康控制点,感知个人控制,焦虑,抑郁,生活满意度和真实性的测量。GCOS-24的同时效度采用双变量相关进行评估。使用方差分析评估GCOS-24变化的敏感性。全民教育确定了一个由七个方面组成的总体结构。内部一致性(α = 0.87)和重测信度(r = 0.86)良好。GCOS-24显示了收敛和发散的有效性,以及对随时间变化的敏感性,具有中等至大的效应量(Cohen d = 0.70)。GCOS-24有可能作为临床遗传学特异性PROM。
The aim of this study was to develop a patient-reported outcome measure (PROM) for clinical genetics services. Previous research was used to develop a draft 84-item questionnaire, which was completed by 527 members of patient support groups. Responses were subjected to exploratory factor analysis (EFA). Parallel analysis was used to identify the number of factors to extract using oblique rotation. Twenty-four questions were selected to form the Genetic Counseling Outcome Scale (GCOS-24). Two hundred and forty-one patients completed a questionnaire pack before and after attendance at a genetics clinic that included the GCOS-24, and validated measures of health locus of control, perceived personal control, anxiety, depression, satisfaction with life and authenticity. Concurrent validity of the GCOS-24 was assessed using bivariate correlation. Sensitivity to change of the GCOS-24 was assessed using analysis of variance. EFA identified a single overarching construct consisting of seven dimensions. Internal consistency (alpha = 0.87) and test-retest reliability (r = 0.86) are good. The GCOS-24 shows convergent and divergent validities, and sensitivity to change over time with a medium-to-large effect size (Cohen's d = 0.70). The GCOS-24 has potential as a clinical genetics-specific PROM.